Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Comparative Study Between Thymomatous and Non-Thymomatous Patients

Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Multicenter Comparative Study Between Thymomatous and Non-Thymomatous Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07319689

Enrollment

100

Registered

2026-01-06

Start date

2022-01-01

Completion date

2025-12-18

Last updated

2026-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthenia Gravis, Non-Thymomatous, Predictor, Thoracoscopic Thymectomy, Thymomatous

Brief summary

This study aimed to assess and compare predictors of outcome in patients with thymomatous and non-thymomatous MG undergoing Thoracoscopic thymectomy.

Detailed description

Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness resulting from antibodies that target acetylcholine receptors or associated proteins at the neuromuscular junction. Thoracoscopic thymectomy becomes more prominent than traditional transsternal thymectomy due to fewer perioperative complications with shorter hospital stays and more favorable long-term outcomes. Prognostic outcomes following thoracoscopic thymectomy can vary significantly between non-thymomatous and thymomatous MG, necessitating a thorough investigation of these differences.

Interventions

OTHERData collection

Data were obtained from patient files, operative notes, and electronic medical records.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Both sexes. * Confirmed diagnosis of Myasthenia Gravis (MG). * Underwent Thoracoscopic thymectomy. * Availability of complete preoperative and postoperative records, including imaging and histopathology. * Minimum follow-up of 9 months post-surgery.

Exclusion criteria

* Patients who underwent thymectomy for indications other than MG. * Incomplete medical records or loss to follow-up before outcome assessment. * Patients with concomitant neuromuscular disorders other than MG

Design outcomes

Primary

Measure	Time frame	Description
Proportion of patients achieving complete stable remission	12 months post-procedure	Proportion of patients achieving complete stable remission was recorded.

Secondary

Measure	Time frame	Description
Proportion of patients achieving pharmacologic remission	12 months post-procedure	Proportion of patients achieving pharmacologic remission was recorded.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026